Vancouver, Canada, January 2,2018 LDS Inc. Great
Post# of 60
(Total Views: 765)
Posted On: 01/07/2018 1:09:16 PM
Vancouver, Canada, January 2,2018 LDS Inc.
Great news who will have a big impact; with this in place LDS can expand there customer base globally, step by step. Lifestyle Delivery Systems Inc. announces Enhanced Patent Filing and Additional Trademark Applications in United Kingdom and European Union.
The new patent filed by Dr. Sanderson, the Company’s Chief Science Officer and the licensor of the CannaStripsTM technology, adds additional enhanced capabilities to the current CannaStripsTM formula, which will be implemented into the 2018 CannaStripsTM product line.
The new trademark applications are intended as an anticipatory action to protect the CannaStripsTM oral strips brand in geographical territories where the Company may have future plans for distribution. The Canadian trademark filing was made back in April 2017, as part of the structural predevelopment plans for possible future product licensing and distribution collaboration or partnership regarding CannaStripsTM technology in Canada.
The Company has made its interest to collaborate on clinical trials in Canada known to a number of Canadian licensed producers (“LP”). Should the Company come to an agreement with a Canadian LP for sponsorship of Canadian clinical trials and subsequently have those trials result in an approval from Health Canada for the CannaStripsTM technology for use in Canada, the Company would focus on a license agreement to introduce CannaStripsTM into the Canadian market.
LDS CEO, Brad Eckenweiler, stated, “We strongly believe that the CannaStripsTM delivery system is so unique that with clinical trials from a recognized health organization to substantiate the efficacy of the technology it would have to be at the top of the list of preferred delivery solutions anywhere in the world.”
The Company will continue to pursue a collaborative effort for clinical trials with the intent on accomplishing commencement of those clinical trials in the first quarter of 2018. (Told you... soon it`s 1 year of clinical trials - if they are promising that will be a new catalyst of the stock !
Considering the progress of Lifestyle Delivery Systems business idea and execution - I would not be surprised if it doubled up again within this month. Be sure of there are pharma business and instituional money following this one closely.
Great news who will have a big impact; with this in place LDS can expand there customer base globally, step by step. Lifestyle Delivery Systems Inc. announces Enhanced Patent Filing and Additional Trademark Applications in United Kingdom and European Union.
The new patent filed by Dr. Sanderson, the Company’s Chief Science Officer and the licensor of the CannaStripsTM technology, adds additional enhanced capabilities to the current CannaStripsTM formula, which will be implemented into the 2018 CannaStripsTM product line.
The new trademark applications are intended as an anticipatory action to protect the CannaStripsTM oral strips brand in geographical territories where the Company may have future plans for distribution. The Canadian trademark filing was made back in April 2017, as part of the structural predevelopment plans for possible future product licensing and distribution collaboration or partnership regarding CannaStripsTM technology in Canada.
The Company has made its interest to collaborate on clinical trials in Canada known to a number of Canadian licensed producers (“LP”). Should the Company come to an agreement with a Canadian LP for sponsorship of Canadian clinical trials and subsequently have those trials result in an approval from Health Canada for the CannaStripsTM technology for use in Canada, the Company would focus on a license agreement to introduce CannaStripsTM into the Canadian market.
LDS CEO, Brad Eckenweiler, stated, “We strongly believe that the CannaStripsTM delivery system is so unique that with clinical trials from a recognized health organization to substantiate the efficacy of the technology it would have to be at the top of the list of preferred delivery solutions anywhere in the world.”
The Company will continue to pursue a collaborative effort for clinical trials with the intent on accomplishing commencement of those clinical trials in the first quarter of 2018. (Told you... soon it`s 1 year of clinical trials - if they are promising that will be a new catalyst of the stock !
Considering the progress of Lifestyle Delivery Systems business idea and execution - I would not be surprised if it doubled up again within this month. Be sure of there are pharma business and instituional money following this one closely.
(0)
(0)Core One Labs Inc. (CLABF) Stock Research Links
Robert